Home / Focus & sleep / PE 22-28
PeAnimal studies only

PE 22-28 protocol

PE 22-28 is a 7-amino-acid piece of spadin, a peptide that blocks the TREK-1 channel. Researchers designed it to last longer than spadin. It has been tested in cells and mice only.

Not approved anywhereCell and mouse studies only
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

There is no human dose. All findings are from cell and mouse experiments.

ItemWhat the sources show
Human doseNot established
Studied inMice and lab cells

Mouse treatment lasted 4 days in the novelty feeding test. ClinicalTrials.gov lists no PE 22-28 or spadin trial (searched 5 Nov 2026).

Community reports

Community notes report 100 to 300 mcg a day for 4 to 8 weeks. No human study backs this.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing

No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.

What the trials found

No human results exist. Lab and mouse findings:

0.12 nMStrength needed to block human TREK-1 in lab cells (spadin: 40 to 60 nM)
MiceLess time immobile in the forced swim test; faster to eat in a novelty feeding test after 4 days
4 daysTreatment time that raised new-cell growth in mouse brains

Front Pharmacol 2017, PMID 28955242 (spadin analogs; PE 22-28 is the 7-amino-acid analog).

Side effects

  • No human safety data exists.

How it works

TREK-1 channel

It blocks the TREK-1 potassium channel, which is linked to mood in rodent models.

Synapses

In mouse nerve cells it raised PSD-95, a marker of new synapses.

Sources

  • Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Front Pharmacol 2017, PMID 28955242
  • ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results